Louisiana State Employees Retirement System Acquires 300 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Louisiana State Employees Retirement System boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 1.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,800 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Protagonist Therapeutics were worth $1,112,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of Protagonist Therapeutics by 127.2% during the 3rd quarter. Franklin Resources Inc. now owns 81,591 shares of the company’s stock valued at $3,782,000 after acquiring an additional 45,674 shares during the last quarter. New York State Teachers Retirement System bought a new position in shares of Protagonist Therapeutics during the 3rd quarter valued at approximately $1,107,000. Swedbank AB bought a new position in shares of Protagonist Therapeutics during the 3rd quarter valued at approximately $2,250,000. Charles Schwab Investment Management Inc. boosted its position in shares of Protagonist Therapeutics by 7.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company’s stock valued at $25,448,000 after acquiring an additional 39,850 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company’s stock valued at $14,437,000 after acquiring an additional 310,804 shares during the last quarter. 98.63% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Suneel Gupta sold 103,437 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $46.04, for a total transaction of $4,762,239.48. Following the transaction, the insider now owns 256,174 shares in the company, valued at approximately $11,794,250.96. This trade represents a 28.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Arturo Md Molina sold 26,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $44.70, for a total value of $1,162,200.00. Following the transaction, the insider now owns 46,444 shares in the company, valued at approximately $2,076,046.80. This represents a 35.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 207,957 shares of company stock worth $9,611,739. Company insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on PTGX shares. BMO Capital Markets began coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $62.00 target price for the company. StockNews.com downgraded Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. JMP Securities restated a “market outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. Finally, Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Protagonist Therapeutics Stock Down 0.0 %

PTGX stock opened at $38.67 on Tuesday. The business’s fifty day simple moving average is $38.61 and its two-hundred day simple moving average is $41.86. Protagonist Therapeutics, Inc. has a twelve month low of $24.22 and a twelve month high of $48.89. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of 14.54 and a beta of 2.22.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.